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Abstract Fumonisins are fungal toxins found in corn and in
corn-based foods. Fumonisin B1 (FB1) is the most common
and is toxic to animals, causes cancer in rodents, and is a
suspected risk factor for cancer and birth defects in humans.
The hydrolyzed form of FB1 (HFB1) also occurs in foods and
is metabolized by rats to compounds collectively known as N-
acyl-HFB1 (also known as N-acyl-AP1). N-acyl-HFB1 is
structurally similar to ceramides, metabolites which have im-
portant structural and signaling functions in cells. FB1 is N-
acylated in vitro to ceramide-like metabolites which, like FB1,
are cytotoxic. However, metabolism of FB1 and inhibition of
ceramide synthase by its metabolites in vivo has not been
demonstrated. Male rats were dosed ip with 0.5, 1, or
2 mg/kg body weight FB1 on five consecutive days and the
liver and kidney thereafter processed for chemical analysis.N-
acyl derivatives of fumonisin B1 were identified for the first
time in these principal target organs of FB1 in rats, at levels up
to 0.4 nmol/g tissue using mass spectrometry. The N-acyl
chain length of the metabolites varied in a tissue-dependent
manner with C16 derivatives predominating in the kidney and
C24 derivatives being prevalent in the liver. The toxicological
significance of N-acyl-fumonisins is not known and warrants
investigation.
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Fumonisins are secondary metabolites of fungi, mainly Fusar-
ium verticillioides and Fusarium proliferatum. They were de-
scribed for the first time by Gelderblom et al. (1988) who
isolated and characterized fumonisin B1 (FB1) by means of a
biosassay based on the promotion of carcinogenesis in rat liver.
Further studies demonstrated that FB1, the most prevalent con-
gener, is hepato- and nephrotoxic to rodents (Voss et al.
1989; Voss et al. 2001). In addition, several species-specific
syndromes are caused by FB1. These include neural tube de-
fects in the LM/Bcmouse (Voss et al. 2009; Gelineau-vanWaes
et al. 2009; Gelineau-van Waes et al. 2005; Gelineau-van Waes
et al. 2012), equine leukoencephalomalacia (Marasas et al.
1988), and pulmonary edema in pigs (Harrison et al. 1990).
Fumonisins are structurally similar to the sphingoid bases
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sphinganine and sphingosine, andWang et al. (1991) found that
FB1 inhibits ceramide synthase (CerS), a critical enzyme in the
de novo biosynthesis of ceramide and complex sphingolipids,
and disrupts sphingolipid metabolism. These and subsequent
studies have established disrupted sphingolipid metabolism as
the mode of action of fumonisins (Bulder et al. 2012).
In a previous study, Humpf et al. (1998) found that
hydrolyzed FB1 (HFB1), an alkaline hydrolysis product
of FB1 that is present in some foods, is a substrate for
CerS in rat liver microsomes (Humpf et al. 1998).
Specifically, HFB1 substitutes for sphinganine or sphin-
gosine so that CerS catalyzes the acylation of HFB1 at
the primary amino group with fatty acids of various
chain lengths to form ceramide analogs known as N-
acyl-HFB1 (NAHFB1). HFB1 was also metabolized
in vivo: NAHFB1 of various fatty acyl chain lengths
were found in the liver and kidney of rats exposed to
HFB1 (Seiferlein et al. 2007). Harrer et al. (2013), using
an optimized mass spectrometry method, more recently
demonstrated the in vitro formation of N-acyl-FB1
(NAFB1) in human cell l ines which had been
transfected for the overexpression of CerS. We now
report the in vivo formation of NAFB1 in rats exposed
to FB1.
Materials and methods
Animals and experimental design
The study protocol was approved by the Institutional Animal
Care and Use Committee, Richard B. Russell Agricultural
Research Center, Athens, GA. Male Sprague–Dawley rats
(Harlan Industries, Indianapolis, IN, USA), 7 weeks of age
at receipt, were individually housed in stainless steel, wire
mesh cages in an environmentally controlled room having a
12-h light/dark cycle. Food (2019 Global Rodent Diet, Teklad,
Madison, WI, USA) and fresh tap water were provided ad
libitum. After a 1 week acclimation period, the animals were
randomly assigned to five groups (n=2/group) having mean
weights of 215 to 216 g (weight range of all animals, 211 to
220 g). For five consecutive days, they were observed,
weighed, and given an intraperitoneal injection (ip) of 0
(vehicle), 0.5, 1.0, or 2.0 mg/kg body weight FB1 (provided
by R. Eppley, US FDA), 1.0 mg/kg body weight HFB1
(positive control) (Voss et al. 2009), or vehicle (0.9 % phys-
iological saline). These doses corresponded to 0.69, 1.38, and
2.77 μmol FB1/kg body weight and 2.47 μmol/kg body
weight HFB1 per day. In order to compare the effects of FB1
and HFB1, dosages will be expressed as molar concentrations
and, on this basis, the high dose of FB1 is roughly equivalent
to that of the positive control dose of HFB1. Dosing solutions
were sterile filtered and administered at a volume rate of
10 ml/kg body weight. The animals were fasted overnight
prior to administration of the final dose. The rats were eutha-
nized (CO2 inhalation and exsanguination) 60 to 90 min fol-
lowing the final dose administration and examined by necrop-
sy. The kidney and liver specimens were fixed in 10% neutral
buffered formalin, processed, and microscopically evaluated
without knowledge of the animal’s identity or treatment
group. Three representative liver and kidney specimens
(100 mg each) were also collected, immediately frozen, and
stored (−80 °C) until processed, at which time the tissues were
thawed and homogenized in distilled/deionized water (1 ml
water/100 mg tissue). The homogenates were lyophilized
before they were shipped by overnight courier for the analysis
of fumonisin metabolites and sphingolipids.
Chemicals and reagents
Reverse phase columns were from Phenomenex
(Aschaffenburg, Germany) and Varian (Darmstadt, Germany).
All chemicals and solvents were analytical grade and pur-
chased from Sigma-Aldrich (Steinheim, Germany).
Sphingolipid standards are from Avanti Polar Lipids (Alabas-
ter, USA). FB1, HFB1, NAFB1, NAHFB1, and the isotope-
labeled standard FB1-d6 were isolated and synthesized with
methods described earlier (Lukacs et al. 1996; Hübner et al.
2012; Harrer et al. 2013).
Quantification of NAFB1, NAHFB1, and sphingolipids
Lyophilized liver and kidney tissues (100 mg wet weight
equivalents) were processed for the quantification of FB1,
HFB1, NAFB1, NAHFB1, and sphingolipids. Preparation of
the tissue samples was performed according to a previously
published method (Harrer et al. 2013). For the quantification
of FB1 and HFB1, a d6-labeled derivative of FB1 (FB1-d6) was
used as the internal standard. Synthetic derivatives with a
heptadecanoic fatty acid (C17:0) residue were used as internal
standards for the quantification of N-acyl-fumonisins and
ceramides (N-C17:0-FB1, N-C17:0-HFB1, and N-C17:0-cer-
amide). The sphingoid bases and their phosphate derivatives
were quantified using synthetic derivatives with a C17-acyl-
backbone: sphingosine (C17:1), sphingosine-1-phosphate
(C17:1), sphinganine (C17:0), sphinganine-1-phosphate (C17:0)
as internal standards. The standards were dissolved in
methanol:chloroform (2:1, v/v) and then mixed with the tissue
samples. The samples spiked with internal standard were kept
at room temperature for 30 min before being processed fur-
ther. The internal standard-spiked samples were first extracted
with ethyl acetate, isopropanol, and water (60:30:10, v/v/v)
and a second time using methanol, chloroform, and water
(60:30:10, v/v/v). The extracts were combined, the solvents
removed by evaporation, and the dried samples stored at
−80 °C till analyzed.
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For the analysis, the samples were reconstituted in a mix-
ture of water, methanol, and tetrahydrofurane (60:24:16, v/v/
v). The NAFB1 and NAHFB1 derivatives having the follow-
ing fatty acyl chain lengths were quantified by HPLC-MS/
MS: C16:0, C18:0, C20:0, C22:0, C24:0, C26:0. Furthermore, we
also quantified the unsaturated derivatives C24:1 and C26:1.
The results are given as the sum of all N-acyl derivatives of
FB1 or HFB1. Quantitative results for each individual N-acyl
derivative are given in Table S1 of the Supplementary
Material.
Results and discussion
Histological examination of rat liver and kidney
Mild tomoderate apoptotic, mitotic, and other effects consistent
with fumonisin exposure (Bulder et al. 2012; Voss et al. 2001)
were found in all rats given FB1. Dose-related differences in
severity were not obvious, likely as a consequence of the small
sample size of n=2/group and dosing regimen (levels and
exposure route). In agreement with reports that HFB1 is less
toxic than FB1 in rodents (Gelderblom et al. 1993; Collins et al.
2006; Howard et al. 2002; Voss et al. 2009), the microscopic
appearance of the kidneys and liver from rats given 1.0 mg/kg
body weight HFB1 per day could not be differentiated from that
of tissues from the vehicle control group.
Tissue FB1 and HFB1 concentrations
In order to evaluate the metabolism of fumonisins, the con-
centrations of FB1, HFB1, and their metabolites were deter-
mined in the kidney and liver. No fumonisins or metabolites
were detected in the animals given the vehicle (see Fig. 1). In
the FB1-exposed groups, a dose-dependent increase in FB1
concentrations was found in the kidneys that ranged from 4 to
up to 10 nmol/g tissue. The average concentrations of FB1 in
the liver were 12- to 20-fold lower (see Fig. 1). This pattern of
preferential accumulation of FB1 in the kidney is consistent
with previously published data (Riley and Voss 2006) show-
ing that the FB1 concentration (ng/g wet weight) in the kidney
of rats fed with fumonisin-contaminated diet was approxi-
mately tenfold higher than that in the liver. Our findings are
also consistent with those of a single-dose toxicokinetic study
of FB1 (Martinez-Larranaga et al. 1999) in which area under
the concentration–time curve (AUC)tissue/AUCplasma ratios
of 29.9 and 2.03 were determined for the kidney and liver,
respectively.
A different pattern was found for HFB1. Its molar concen-
tration in the liver was about sixfold higher than the concen-
tration in the kidney (1.78 nmol/g in the liver and 0.27 nmol/g
in the kidney, see Fig. 1).
In vivo formation of NAFB1 and NAHFB1
N-acyl derivatives of fumonisins having various acyl chain
lengths were found in animals treated with FB1 or HFB1,
demonstrating for the first time the in vivo formation of N-
acyl-FB1 in fumonisin’s two main target organs in rats (see
Fig. 2). No metabolites have been observed in the vehicle-
treated (control) animals.
The NAFB1 levels (expressed as the sum of all N-acyl
derivatives) varied only slightly and ranged from 0.18 to
0.38 nmol/g. The amount of HFB1 metabolites in the liver
was sixfold higher than that in the kidneys: the organs’ re-
spective NAHFB1 concentrations were 2.8 and 0.5 nmol/g
tissue (see Fig. 2). Very low amounts of NAHFB1 (<0.1 nmol/
g tissue) were also detected in the tissues of animals given
FB1. Their source was not determined although it can be
speculated that they resulted from absorption and metabolism
of HFB1 that had been formed from hydrolysis of FB1 by the
intestinal microbiota (Shephard et al. 1994 and 1995). How-
ever, the possibility that enzymatic hydrolysis of small
amounts of absorbed FB1 provided a pool of HFB1 in the
tissues cannot be discounted.
Total FB1 and HFB1 species in the kidney and liver
The tissue burdens of FB1, HFB1, and N-acyl metabolites in
the kidney and liver after 5 days of exposure represented only
a small fraction of the administered FB1 or HFB1. Differences
in the accumulation in these target organs were apparent (see
Fig. 3). Only 0.1 to 0.3 % of the total dose (TD) was recovered
from the liver as unmetabolized FB1 while the amount found
in the kidney was slightly higher, ranging from about 0.5 to
slightly less than 0.8 % of TD. Compared to the high dose of
FB1, a relatively high amount of unmetabolized HFB1, 0.7 %
TD, accumulated in the liver and a relatively lower amount,
<0.1 % TD of HFB1, in the kidney.
N-acyl-FB1 species in the liver ranged from 0.1 (low- and
high-dose groups) to about 0.3 % TD (low-dose group) on a
μmolar basis. Although low, these amounts represented 35 to
60 % of the total FB1 species in the liver (see Fig. 3). Only
insignificant amounts of the FB1 species (<0.04 % TD and
<10% of FB1 species in the kidney) found in the kidneys were
N-acyl metabolites. In contrast, N-acyl-HFB1 species in the
liver accounted for 1.1% TD, but, as was the case for FB1, this
amount made up about 60 % of the total HFB1 species
recovered in the liver. Similar to FB1 and its metabolites, the
total amount of HFB1 species in the kidney was negligible and
represented only 0.03 % TD. However, in contrast to the low
contribution of metabolites to total renal FB1 species, 65 % of
the HFB1 found in the kidney consisted ofN-acyl metabolites.
The high dose of FB1 (2.77 μmol/kg body weight) and the
HFB1 dose (2.47 μmol/kg body weight) were approximately
equal, and, when comparing the results from these treatment
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groups, it was apparent that the kidney accumulated FB1
much more readily than HFB1. The results also suggest
that the kidney has only a limited capacity to metabolize
both mycotoxins as less than 0.5 nmol/g of FB1, or HFB1
metabolites were found. The male rat kidney is recognized
as being extremely sensitive to the apoptotic and other
effects of FB1 (Howard et al. 2001; Dragan et al. 2001).
Nephrotoxicity has therefore served as a sentinel of expo-
sure for applied studies (Burns et al. 2008; Voss et al. 2011)
and has also provided a benchmark dose for risk assess-
ment (Bulder et al. 2012).
Tissue specificity of N-acylation of fumonisins
Different isoforms of CerS exist in the tissues of mammalian
organisms. All are tissue specific, catalyze the N-acylation of
sphinganine, and are specific for coenzyme A fatty acid
cosubstrates having fatty acid residues that vary in length from
C14 to C26 (Pewzner-Jung et al. 2006). We therefore analyzed
the individual levels of ceramides and NAFB1 and NAHFB1
metabolites of differentN-acyl chain lengths in the kidney and
the liver of FB1- or HFB1-exposed rats.
The amounts of ceramide species found in the two tissues
were different with C16 derivatives beingmore predominant in
the kidney. In contrast, CerS isoforms in the liver generated
mainly C24-ceramides (all quantitative results for each indi-
vidual N-acyl derivative can be found in Table S1 the Supple-
mentaryMaterial). It is of interest that the ratio ofN-C16- toN-
C24-fumonisin derivatives in the kidney and liver was consis-
tent with that of the ceramides found in each tissue (see
Fig. 4). It can therefore be concluded that NAFB1 and
NAHFB1 found in the liver and kidney were most likely
products of reactions catalyzed by the CerS isoforms specific
to those tissues. The gene expression of the CerS isoforms and
Fig. 1 Themolar concentrations of FB1 andHFB1 in the kidney and liver
of rats. The animals were treated by intraperitoneal injection of FB1 or
HFB1 for 5 days with doses of 0.69, 1.38, and 2.77 μmol FB1/kg body
weight per day and 2.47μmol/kg body weight HFB1 per day. The dose of
HFB1 is the molar equivalent to the high dose group of FB1. FB1 and
HFB1 in the tissues were quantified by HPLC-ESI-MS/MS. Values are
means±S.D. (n=2). Note the difference in scale, y-axis. FB1 or HFB1
were not detected in tissues of vehicle-treated (control) rats
Fig. 2 The concentrations of NAFB1 and NAHFB1 in the kidney and
liver of rats (expressed as the sum of allN-acyl derivatives). Animals were
treated by intraperitoneal injection of FB1 or HFB1 for 5 days with doses
of 0.69, 1.38, and 2.77 μmol FB1/kg body weight per day or 2.47 μmol/
kg body weight HFB1 per day. The dose of HFB1 is the molar equivalent
to the high dose group of FB1. NAFB1 and NAHFB1 were analyzed by
HPLC-ESI-MS/MS. Values are means±S.D. (n=2). Note the difference
in scale, y-axis
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the concordant ceramide pattern is well understood for the
renal and hepatic tissue of mice. From the data of Laviad et al.
(2008), it is seen that in the kidney of mice, the predominant
ceramide species are the N-C16 derivatives and in the liver the
N-C24 derivatives. Our data indicate that the ceramide pattern
is consistent among mouse and rat tissues. However, there is
no established knowledge about the chain length distribution
and the gene expression of CerS isoforms in rats. Therefore, it
could be interesting to verify these observations in further
studies.
Sphingolipids
Inhibition of CerS by FB1 is the key event in fumonisins’
mode of action (Dragan et al., 2001, Bulder et al., 2012).
Inhibition disrupts overall sphingolipid metabolism, resulting
in increased concentrations of sphinganine, sphingosine, and
their 1-phosphates and decreased levels of ceramide and com-
plex sphingolipids in tissues in vivo (Voss et al. 2009) and in
cultured cells (Wang et al. 1991). The levels of several
sphingolipids were therefore analyzed in the samples, and,
as expected (Riley and Voss 2006), the rats responded to FB1
with increased amounts of total sphingosine (sphingosine plus
sphingosine-1-phosphate), total sphinganine (sphinganine
plus sphinganine-1-phosphate) (see Fig. 5), and the individual
sphingoid bases and 1-phosphate metabolites in the tissues
(see Table 1). In contrast, treatment with HFB1 did not cause
any significant changes in the levels of the sphingolipids
compared to the vehicle-treated controls (see Fig. 5 and Ta-
ble 1). The FB1 modified sphingolipid profiles in the
liver and kidney differently. The two sphingoid bases
and their 1-phosphates were increased somewhat in the
liver and much more extensively in the kidney whereas
tissue ceramide concentrations were decreased in both
tissues, with levels in the liver tending to be slightly
lower (see Fig. 5 and Table 1). A limited number of
in vitro studies have shown that NAHFB1 metabolites of
HFB1 alter sphingolipid concentrations in various cell
lines, including those overexpressing CerS isoforms
(Seefelder et al. 2003; Harrer et al. 2013), and also were
cytotoxic to IHKE human proximal tubule-derived cells
(Seefelder et al. 2003) and other mammalian cell lines
(Harrer et al. 2013). Whether or not NAFB1 and NAHFB1
metabolites contribute to toxicity in vivo is not known
and requires further investigation. That HFB1 treatment in
this study did not significantly alter tissue sphingolipid
Fig. 3 The relative accumulation
of FB1 and HFB1 (gray bars) and
theirN-acyl metabolites (black) in
the kidney and the liver after
5 days of exposure to the parent
mycotoxin. The dose groups were
0.69, 1.38, and 2.77 μmol FB1/kg
body weight per day and
2.47 μmol/kg body weight HFB1
per day. The dose of HFB1 is a
(approximate) molar equivalent to
the high dose group of FB1.
Values are means±S.D. (n=2)
Fig. 4 The distribution of the
fatty acid chain lengths of N-acyl-
FB1, N-acyl-HFB1, and ceramide
in the kidney and liver of rats.
Values are means (n=2) and
normalized to the sum of C16 and
C24 derivatives found in the
tissues (quantitative results for
each individual N-acyl derivative
can be found in Table S1 of the
Supplementary Material)
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concentrations, is consistent with reports that it exerts a
significantly lesser effect on tissue sphingolipid
profiles, and is less toxic to rats and mice than FB1
(Collins et al. 2006; Howard et al. 2002; Voss et al. 2009).
Fig. 5 The levels of total sphinganine (Sa) plus sphinganine-1-phosphate
(Sa1P), total sphingosine (So) plus sphingosine-1-phospate (So1P), and
ceramide in rat kidney and liver. Animals were treated by intraperitoneal
injection with doses of 0.69, 1.38, and 2.77μmol FB1/kg bodyweight per
day and 2.47 μmol/kg body weight HFB1 per day. The dose of HFB1 is
the approximate molar equivalent of the high dose of FB1. The tissue
samples were extracted, and all analytes were determined by HPLC-ESI-
MS/MS. Values are means±S.D. (n=2)
Table 1 The levels of sphinganine (Sa), sphingosine (So), sphinganine-
1-phosphate (Sa1P), and sphingosine-1-phospate (So1P) and the Sa/So
ratio in rat kidney and liver. Animals were treated by intraperitoneal
injection with doses of 0.69, 1.38, and 2.77 μmol FB1/kg body weight
per day and 2.47 μmol/kg body weight HFB1 per day. The dose of HFB1
is the approximate molar equivalent of the high dose of FB1. The tissue
samples were extracted, and all analytes were determined by HPLC-ESI-
MS/MS. Values are means±S.D. (n=2)
Tissue Substance Dose Sa nmol/g So nmol/g Sa/So ratio Sa1P nmol/g So1P nmol/g
Kidney Control 2±0.7 6±0.4 0.4±0.1 1.6±0.7 1.0±0.1
Kidney FB1 Low 252±15.6 63±11.5 4.1±1.0 16.7±0.5 21.4±4.1
Kidney FB1 Mid 146±11.3 59±8.3 2.5±0.2 11.3±1.5 20.8±0.7
Kidney FB1 High 207±79.9 56±6.2 3.8±1.8 19.9±1.0 21.6±4.5
Kidney HFB1 High 3±0.7 9±2.8 0.3±0.0 0.6±0.4 0.4±0.1
Liver Control 3±0.3 3±0.6 1.0±0.1 0.2±0.0 0.3±0.0
Liver FB1 Low 68±27.6 16±3.3 4.2±0.9 0.2±0.2 0.4±0.2
Liver FB1 Mid 88±15.1 17±6.4 5.5±1.2 0.4±0.1 0.8±0.0
Liver FB1 High 81±17.1 14±2.9 5.9±0.0 0.9±0.5 1.0±0.3
Liver HFB1 High 2±1 3±0.2 0.5±0.4 0.1±0.1 0.2±0.0
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Dosing route and relevance
Given the previous absence of evidence for in vivo FB1
metabolism (other than conversion to HFB1 by gut microflo-
ra) together with its low absorption after oral exposure (<5 %
of dose) (reviewed by Bulder et al. 2012) and low conversion
rate to NAFB1 in vitro (Harrer et al. 2013), multiple high ip
doses were used in this “proof of concept” study. The extent to
which the NAFB1 species are formed and accumulate in
tissues after dietary FB1 exposure in animals or humans is
not known, but is almost certain to be manyfold lower than
that found in this study. It should further be recognized that the
high doses of FB1 or HFB1 possibly compromised tissue
metabolic or transport systems, thereby influencingmetabolite
production and retention. This possibility is especially rele-
vant for the kidney of rats given FB1 because of the mild to
moderate nephrotoxicity induced in these animals. Additional
investigations following oral exposure to physiologically rel-
evant doses are therefore needed to evaluate the role, if any, of
NAFB1 in FB1 toxicity.
Conclusions
This experiment has to our knowledge revealed for the first
time the metabolic conversion of FB1 to a series of NAFB1
species in vivo. Consistent with earlier reports, much more
FB1 was recovered from the kidneys than from the liver. Renal
FB1 was however almost exclusively unmetabolized whereas
approximately half of the FB1 in the liver consisted of N-acyl
species, suggesting that metabolic turnover might occur more
readily in the liver. Furthermore, the acylation pattern, that is,
the chain lengths of the fatty acid moieties of the metabolites,
recovered from the two organs differed, likely as a result of
different isoforms of ceramide synthase that predominate in
the two tissues. Metabolism of FB1 differed in some respects
from that of HFB1. It is noteworthy that, in contrast to FB1,
over half of the HFB1 species found in the kidney were
metabolites, an observation suggesting the possibility that
metabolism contributes to the relatively lower nephrotoxicity
of HFB1. Sphingolipid metabolism was markedly disrupted
by FB1 while tissues sphinganine, sphingosine, sphingoid
base 1-phosphate, and ceramide concentrations in the tissues
of rats dosed with HFB1 were similar to those in vehicle-
treated rats. The contribution of fumonisin metabolites to
toxicity is not known and warrants further study.
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